EMILIN1 Antibody

What is EMILIN1 and what are its key structural domains?

EMILIN1 is an extracellular matrix glycoprotein with a molecular mass of approximately 106.7 kilodaltons. It belongs to a family of proteins associated with elastic fibers and is also known as EMI, EMILIN, gp115, and elastin microfibril interface-located protein 1 . The protein contains several distinct structural domains that contribute to its functional versatility:

• The N-terminal Elastin Microfibril Interface (EMI) domain, which interacts with pro-TGF-β

• A central α-helical region with coiled-coil structural potential

• The C-terminal globular domain of C1q (gC1q domain), which mediates EMILIN1 oligomerization, cell adhesion, and interactions with α4β1 and α9β1 integrins

These domains enable EMILIN1 to participate in multiple cellular processes including cell adhesion, migration, and proliferation regulation through both integrin engagement and modulation of TGF-β signaling pathways.

Which biological processes involve EMILIN1 function?

EMILIN1 participates in numerous biological processes critical for tissue development and homeostasis:

• Elastogenesis and maintenance of blood vessel morphology through association with elastic fibers

• Regulation of lymphatic vessel growth and integrity, with EMILIN1 deficiency leading to lymphatic vessel hyperplasia

• Inhibition of dermal fibroblast and keratinocyte proliferation via interaction with α4β1 and α9β1 integrins, which maintains skin homeostasis

• Modulation of TGF-β signaling by binding to pro-TGF-β, affecting downstream pathways including PTEN, PI3K/Akt, and Erk1/2

• Promotion of trophoblast invasion during placental development through interaction with α4β1 integrin

• Regulation of extracellular matrix organization, particularly in association with elastic fibers in various tissues

The diverse functions of EMILIN1 underscore its importance in both developmental processes and tissue maintenance throughout adult life.

What tissue distribution pattern is characteristic of EMILIN1?

EMILIN1 displays a distinctive tissue distribution pattern that correlates with its functional roles:

• Highest abundance in the walls of large blood vessels where it associates with elastic fibers

• Prominent presence in dermal stroma, with EMILIN1-positive fibrils extending to the basal keratinocyte layer

• Significant expression in intestine, lung, and lymph nodes

• Notable presence in lymphatic vessels, where it contributes to anchoring filament formation

• Detection in the placenta, specifically in both chorionic villi and decidua during early pregnancy

• Expression in the ectoplacental cone and trophoblast giant cells during embryonic development

This distribution pattern suggests that EMILIN1 plays particularly important roles in tissues requiring elasticity and those undergoing active remodeling during development or physiological processes.

What applications are most suitable for EMILIN1 antibodies in research?

EMILIN1 antibodies can be employed in multiple experimental contexts depending on research objectives:

When selecting an antibody, researchers should consider the specific application requirements, the epitope recognized (particularly for domain-specific studies), and validation data available for the antibody in the intended application .

How should researchers validate the specificity of EMILIN1 antibodies?

Thorough validation of EMILIN1 antibodies is essential to ensure experimental reliability:

• Western blot validation:

  • Confirm detection of a single band at approximately 106.7 kDa in tissues known to express EMILIN1

  • Include positive controls (vascular tissue extracts) and negative controls (tissues or cells with EMILIN1 knockdown)

  • Perform peptide competition assays to verify specific binding

• Immunohistochemical validation:

  • Compare staining patterns with published EMILIN1 distribution data

  • Include parallel staining of EMILIN1-knockout tissues when available

  • Test antibodies targeting different EMILIN1 epitopes to confirm consistent localization patterns

• Cross-reactivity assessment:

  • Test reactivity against related family members to ensure specificity for EMILIN1

  • Verify species cross-reactivity if working with non-human models (mouse, rat)

• Functional validation:

  • For blocking antibodies, confirm inhibition of EMILIN1-dependent functions (e.g., cell adhesion to EMILIN1 substrates)

  • Correlate protein detection with mRNA expression data in the same samples

These validation steps provide confidence in the specificity and reliability of EMILIN1 antibodies, particularly important given EMILIN1's structural similarity to other family members.

What protocols optimize EMILIN1 detection in tissue sections?

For optimal detection of EMILIN1 in tissue sections, the following protocol recommendations should be considered:

• Tissue preparation:

  • Fresh-frozen sections: Fix briefly (10-15 minutes) in 4% paraformaldehyde

  • Paraffin-embedded sections: Use standard formalin fixation with antigen retrieval

  • Section thickness: 5-7 μm optimal for ECM protein visualization

• Antigen retrieval optimization:

  • Heat-induced epitope retrieval with citrate buffer (pH 6.0)

  • Enzymatic retrieval with proteinase K may better expose some EMILIN1 epitopes

  • Optimize retrieval time carefully (typically 10-20 minutes)

• Blocking and antibody incubation:

  • Block with 5-10% normal serum matching secondary antibody species

  • Include 0.1-0.3% Triton X-100 for improved antibody penetration

  • Incubate primary antibody overnight at 4°C at optimized dilution

  • Use fluorophore-conjugated or HRP-labeled secondary antibodies depending on detection method

• Signal detection:

  • For chromogenic detection: DAB (3,3'-diaminobenzidine) with hematoxylin counterstain

  • For fluorescence: Use appropriate fluorophores with DAPI nuclear counterstain

  • Consider signal amplification methods for low-abundance detection

Optimization of these parameters is crucial for accurate EMILIN1 detection while minimizing background and ensuring reproducibility across experiments.

How can co-immunostaining approaches reveal EMILIN1 interactions?

Co-immunostaining techniques can provide valuable insights into EMILIN1's interactions and functions:

• EMILIN1 and cell-type markers:

  • Co-stain for EMILIN1 with keratinocyte markers (K5, K1) to investigate epithelial-stromal interactions

  • Use vascular cell markers (CD31, αSMA) to examine EMILIN1's relationship with different vessel components

  • Combine with proliferation markers (Ki67, BrdU) to assess growth regulatory effects

• EMILIN1 and receptor visualization:

  • Co-localize EMILIN1 with α4β1 and α9β1 integrins to identify potential interaction sites

  • Examine proximity to TGF-β pathway components to understand signaling regulation mechanisms

• EMILIN1 and other ECM components:

  • Co-stain with elastin and fibrillin to investigate elastic fiber association

  • Combine with basement membrane markers (laminin, collagen IV) to study epithelial-matrix interactions

• Technical considerations:

  • Use antibodies raised in different host species to allow simultaneous detection

  • Apply sequential staining protocols for antibodies from the same species

  • Employ spectral unmixing for multi-color imaging to minimize bleed-through

These approaches can reveal spatial relationships between EMILIN1 and its functional partners, providing context for understanding its diverse biological roles.

How can EMILIN1 antibodies elucidate the protein's role in TGF-β signaling?

EMILIN1 modulates TGF-β signaling through its EMI domain interaction with pro-TGF-β. Researchers can investigate this role using the following approaches:

• Inhibition studies with domain-specific antibodies:

  • Apply antibodies targeting the EMI domain to block pro-TGF-β interaction

  • Monitor effects on TGF-β-responsive gene expression and Smad phosphorylation

  • Compare with effects of TGF-β receptor inhibitors to distinguish direct vs. indirect effects

• Signaling pathway analysis:

  • Examine how EMILIN1 antibody blockade affects phosphorylation of Smad2, particularly at residues Ser245/250/255

  • Analyze downstream effects on PTEN expression, PI3K/Akt activation, and Erk1/2 phosphorylation

  • Investigate signaling differences between wild-type cells and those with EMILIN1 knockdown

• In vivo validation:

  • Compare TGF-β signaling markers in tissues from wild-type vs. EMILIN1 knockout mice

  • Use tissue-specific delivery of EMILIN1 antibodies to examine local effects on TGF-β activity

  • Correlate EMILIN1 distribution with areas of active TGF-β signaling

These approaches can help delineate the precise mechanisms by which EMILIN1 regulates TGF-β activity in different cellular contexts, providing insights into potential therapeutic interventions for TGF-β-related disorders.

What techniques best reveal EMILIN1's role in cell proliferation control?

EMILIN1 has been shown to inhibit cell proliferation through interaction with α4β1 and α9β1 integrins. The following methodological approaches can elucidate this function:

• Comparative substrate studies:

  • Culture cells on surfaces coated with recombinant EMILIN1 gC1q domain vs. other substrates

  • Measure BrdU incorporation to quantify proliferation inhibition

  • Analyze proliferation of cells grown in co-culture with EMILIN1-expressing or EMILIN1-silenced cells

• Tissue proliferation analysis:

  • Compare Ki67 immunoreactivity in tissues from wild-type vs. EMILIN1 knockout mice

  • Examine expression of proliferation-associated markers like Keratin K6 in relation to EMILIN1 distribution

  • Analyze both basal and suprabasal cell proliferation in stratified epithelia

• Molecular mechanism investigation:

  • Examine how EMILIN1-integrin engagement affects cell cycle regulatory proteins

  • Track activation of PI3K/Akt and MAPK pathways following EMILIN1 binding to integrins

  • Analyze the relationship between EMILIN1-mediated PTEN regulation and cell cycle progression

• Function-blocking studies:

  • Apply antibodies targeting the gC1q domain to block integrin interactions

  • Use integrin-blocking antibodies to determine which integrin is primarily responsible for proliferation inhibition

  • Examine the effect of soluble recombinant gC1q domain vs. immobilized protein

These approaches can help define the molecular mechanisms underlying EMILIN1's antiproliferative effects and identify potential applications in conditions characterized by dysregulated cell growth.

How do in vitro models compare with in vivo approaches for EMILIN1 research?

Both in vitro and in vivo approaches offer complementary insights into EMILIN1 functions, each with distinct advantages:

For comprehensive understanding of EMILIN1 functions, researchers should ideally combine approaches - using in vitro studies to define molecular mechanisms and in vivo models to validate physiological relevance .

What insights have EMILIN1 knockout studies revealed about skin homeostasis?

Studies using EMILIN1 knockout mice have provided significant insights into the protein's role in skin homeostasis:

• Proliferation regulation:

  • EMILIN1-/- mice display marked increases in Ki67-positive nuclei in both epidermis and dermis

  • Proliferation extends beyond the basal layer to involve suprabasal keratinocytes

  • Expression of proliferation-associated Keratin K6 is detected in both basal and suprabasal layers

• Differentiation effects:

  • EMILIN1-/- mice show altered expression patterns of differentiation markers

  • Suprabasal keratinocytes demonstrate abnormal co-expression of K5 and K1

  • Terminal differentiation marker loricrin remains normally expressed in the most superficial layers

• Structural integrity:

  • Despite proliferation abnormalities, basement membrane components (laminin-5, nidogen, collagen IV) maintain normal distribution

  • Cell junction proteins (β-catenin, occludin, ZO-1) remain normally expressed

  • β4 integrin expression is preserved in basal keratinocytes

• Functional outcomes:

  • Epidermal barrier function is maintained despite proliferation and differentiation abnormalities

  • EMILIN1-/- mice display skin hyperplasia without compromised skin integrity

  • Accelerated wound closure is observed in knockout animals

These findings suggest that EMILIN1 acts as a negative regulator of skin cell proliferation without significantly affecting differentiation programs or barrier function, highlighting its role in maintaining balanced tissue growth rather than structural integrity.

How can researchers investigate EMILIN1's role in placental development?

The involvement of EMILIN1 in placental development can be investigated through several methodological approaches:

• Immunolocalization studies:

  • Map EMILIN1 distribution throughout placental development stages

  • Co-stain with trophoblast markers to identify specific cell populations interacting with EMILIN1

  • Examine EMILIN1 localization in relation to maternal spiral arteries and anchoring villi

• Trophoblast invasion models:

  • Use Transwell migration assays with EMILIN1-coated membranes

  • Apply domain-specific antibodies to block particular EMILIN1 functions

  • Compare migration of trophoblasts on different ECM components including EMILIN1

• In vitro co-culture systems:

  • Establish decidual cell-trophoblast co-cultures with varying EMILIN1 expression

  • Examine trophoblast behavior when cultured with EMILIN1-silenced decidual cells

  • Analyze integrin expression patterns in relation to EMILIN1 responsiveness

• Ex vivo explant cultures:

  • Culture placental explants on EMILIN1-containing matrices

  • Apply function-blocking antibodies against EMILIN1 or its receptors

  • Monitor trophoblast outgrowth and differentiation patterns

• Pathological correlation:

  • Compare EMILIN1 distribution in normal vs. pathological placentas (preeclampsia, growth restriction)

  • Analyze whether EMILIN1 abnormalities correlate with trophoblast invasion defects

  • Examine potential therapeutic applications targeting EMILIN1-integrin interactions

These approaches can provide comprehensive insights into how EMILIN1 contributes to normal placental development and potentially to pregnancy complications characterized by defective trophoblast invasion or placental development.

How should researchers interpret EMILIN1 staining patterns in complex tissues?

Interpreting EMILIN1 staining patterns requires consideration of its diverse functions and structural relationships:

• Vascular contexts:

  • Circumferential staining around blood vessels indicates association with elastic laminae

  • Patchy distribution may suggest areas of active vascular remodeling

  • Co-localization with elastic fiber components confirms structural integration

• Dermal-epidermal interface:

  • EMILIN1-positive fibrils extending to the basal keratinocyte layer suggest a regulatory role

  • Distribution relative to the basement membrane indicates potential interactions with basal cells

  • Patterns may vary with skin region and developmental stage

• Cellular vs. matricellular localization:

  • Discern between cellular expression and extracellular deposition

  • New synthesis may appear as perinuclear/cytoplasmic while mature EMILIN1 appears as extracellular fibrils

  • Orientation of fibrils may indicate tension directions or cell migration paths

• Placental interpretation:

  • In placenta, distribution in decidua and around anchoring villi suggests roles in trophoblast invasion

  • Perivascular localization may indicate involvement in spiral artery remodeling

  • Relative abundance in different placental compartments provides functional insights

When analyzing patterns, researchers should consider tissue-specific architecture, developmental stage, and pathological context, as these factors can significantly influence EMILIN1 distribution and function.

What controls are essential for reliable EMILIN1 antibody experiments?

Proper controls are crucial for ensuring reliable and interpretable results with EMILIN1 antibodies:

For Western blot applications, additional controls include loading controls (β-actin, GAPDH) and molecular weight markers to confirm the detected band matches EMILIN1's expected size (106.7 kDa) .

Implementing these controls systematically helps distinguish specific signal from background and validates antibody performance across different experimental conditions.

How can researchers address common technical challenges with EMILIN1 antibodies?

Several technical challenges can arise when working with EMILIN1 antibodies. Here are effective troubleshooting approaches:

• Weak or absent signal:

  • Optimize antigen retrieval conditions (try both heat-induced and enzymatic methods)

  • Increase antibody concentration or incubation time

  • Use signal amplification systems (tyramide signal amplification, polymer detection)

  • Ensure tissue fixation is not excessive, which can mask epitopes

• High background:

  • Increase blocking duration and stringency (try different blocking agents)

  • Lengthen and intensify wash steps (add detergent to wash buffers)

  • Further dilute primary antibody while extending incubation time

  • Pre-absorb antibody against tissues lacking EMILIN1 expression

• Inconsistent staining:

  • Standardize tissue processing methods (fixation time, embedding protocols)

  • Prepare all samples identically for comparative studies

  • Use automated staining platforms for better reproducibility

  • Include internal control tissues in each experimental batch

• Non-specific bands in Western blots:

  • Optimize sample preparation (extraction buffers, protease inhibitors)

  • Increase washing stringency post-antibody incubation

  • Try different blocking agents (milk vs. BSA)

  • Consider using different antibodies targeting distinct EMILIN1 epitopes

• Cross-reactivity with other EMILIN family members:

  • Select antibodies raised against unique regions of EMILIN1

  • Validate specificity using overexpression/knockdown systems

  • Use recombinant protein standards of different family members

These troubleshooting approaches can help overcome common technical obstacles and improve the reliability of EMILIN1 antibody-based experiments.

How should researchers reconcile contradictory findings across EMILIN1 studies?

When confronted with contradictory findings across EMILIN1 studies, researchers should consider several factors:

• Methodological differences:

  • Compare antibody sources, clones, and epitopes targeted

  • Assess fixation and antigen retrieval protocols used

  • Evaluate detection systems (chromogenic vs. fluorescent) and their sensitivity thresholds

  • Consider quantification methods and statistical analyses employed

• Biological variables:

  • Developmental stage variations (embryonic vs. adult expression patterns differ significantly)

  • Species differences (human vs. mouse EMILIN1 may have subtle functional variations)

  • Tissue-specific contexts (EMILIN1 may function differently in various tissue microenvironments)

  • Pathological states (disease conditions may alter EMILIN1 expression or function)

• Experimental model variations:

  • In vitro vs. in vivo approaches (cell culture findings may not directly translate to whole organisms)

  • Acute vs. chronic interventions (transient antibody blocking vs. genetic knockout)

  • 2D vs. 3D culture systems (matrix dimensionality affects integrin signaling)

• Resolution strategies:

  • Reproduce key findings using identical protocols when possible

  • Design experiments that directly address contradictions

  • Combine complementary approaches (e.g., antibody studies in knockout backgrounds)

  • Consider that apparent contradictions may reflect context-dependent functions

Systematic evaluation of these factors can help reconcile discrepancies and develop a more nuanced understanding of EMILIN1's context-dependent functions.

How might EMILIN1 antibodies contribute to understanding vascular disorders?

EMILIN1 antibodies offer valuable tools for investigating vascular pathologies:

• Hypertension mechanisms:

  • EMILIN1 knockout mice display elevated blood pressure due to increased TGF-β signaling

  • Antibodies can track EMILIN1 distribution and potential alterations in hypertensive models

  • Domain-specific blocking antibodies can help determine whether TGF-β regulation or integrin binding is more critical for blood pressure control

• Vascular wall integrity:

  • EMILIN1 contributes to elastic fiber assembly and maintenance

  • Immunostaining can reveal altered EMILIN1 distribution in vascular disease states

  • Correlative studies between EMILIN1 patterns and biomechanical properties can provide insights into structural roles

• Angiogenesis regulation:

  • EMILIN1's effects on endothelial cell behavior may influence new vessel formation

  • Antibodies can be used to monitor EMILIN1 distribution during angiogenic processes

  • Blocking studies can determine whether EMILIN1 promotes or inhibits specific angiogenic steps

• Vascular remodeling:

  • EMILIN1 may regulate smooth muscle cell proliferation during vascular remodeling

  • Immunostaining in models of vascular injury can track temporal changes in EMILIN1 distribution

  • Correlation with proliferation markers can reveal relationships with repair processes

These applications can advance our understanding of EMILIN1's roles in vascular homeostasis and disease, potentially identifying new therapeutic targets for vascular disorders.

What is the potential for targeting EMILIN1-integrin interactions in therapeutic development?

The interaction between EMILIN1 and α4β1/α9β1 integrins represents a potential therapeutic target:

• Antiproliferative applications:

  • EMILIN1's gC1q domain inhibits cell proliferation through integrin binding

  • Recombinant gC1q domain or mimetic peptides could potentially suppress abnormal cell growth

  • Such approaches might be relevant for hyperproliferative conditions including certain dermatological disorders

• Migration modulation:

  • EMILIN1 promotes cell migration through integrin engagement

  • Targeting these interactions could potentially influence tissue remodeling and wound healing

  • Application-specific approaches could either enhance or inhibit migration depending on clinical context

• TGF-β pathway intervention:

  • Indirect effects on TGF-β signaling occur through integrin engagement and subsequent PTEN regulation

  • This represents an alternative mechanism to direct TGF-β targeting

  • Could provide more tissue-specific modulation than global TGF-β inhibition

• Research tools for therapeutic development:

  • Domain-specific antibodies can help identify the most promising epitopes for therapeutic targeting

  • Competitive binding assays using antibodies can screen potential therapeutic compounds

  • In vivo antibody studies can validate targets before development of small molecule or peptide-based therapeutics

Understanding the structural basis and downstream effects of EMILIN1-integrin interactions will be crucial for developing effective therapeutic strategies targeting this axis.

How can advanced imaging techniques enhance EMILIN1 research?

Advanced imaging technologies offer new possibilities for EMILIN1 research:

• Super-resolution microscopy:

  • Techniques like STORM, PALM, and STED provide nanoscale resolution

  • Can reveal detailed organization of EMILIN1 within elastic fibers

  • Enables precise co-localization with binding partners at molecular scale

• Live cell imaging approaches:

  • EMILIN1 tagged with fluorescent proteins can track dynamic deposition

  • Photobleaching techniques (FRAP, FLIP) can assess EMILIN1 mobility in matrices

  • Biosensors can detect conformational changes upon binding to integrins or other partners

• Intravital microscopy:

  • Direct visualization of EMILIN1 dynamics in living tissues

  • Can track interactions with cells in native environments

  • Particularly valuable for studying vascular and lymphatic processes

• Correlative microscopy:

  • Combining light and electron microscopy for ultrastructural context

  • Immunogold labeling can precisely localize EMILIN1 relative to cellular structures

  • Provides insights into structural integration within elastic fibers

• Tissue clearing techniques:

  • Methods like CLARITY and iDISCO enable whole-organ imaging

  • Allow 3D reconstruction of EMILIN1 networks throughout entire tissues

  • Particularly valuable for vascular and lymphatic system analysis

These advanced imaging approaches can provide unprecedented insights into EMILIN1's structural organization and functional interactions in both normal and pathological contexts.